GXE Lakefront Biotherapeutics NV
Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a ph…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
Lakefront Biotherapeutics' Gamgertamig Has Meaningful Opportunity in Rare Autoimmune Diseases, RBC Says Lakefront Biotherapeutics (LKFT) has a "meaningful opportunity" with its asset gamgertamig for the t | ||
 Microsoft upgraded, HubSpot initiated: Wall Street's top analyst calls Microsoft upgraded, HubSpot initiated: Wall Street's top analyst calls | ||
 Lakefront Biotherapeutics Targets 2027 Registrational Trials for Gamgertamig Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) said it plans to begin registrational studies next year for its lead T-cell engager, gamgertamig, following a broad restructuring of its legacy cell-therapy operations and the acquisition of assets from Ouro Medicines. Speaking at M | ||
 ANI Pharmaceuticals (ANIP) Appoints Henry Gosebruch To Its Board ANI Pharmaceuticals (NasdaqGM: ANIP) appointed biotechnology executive Henry Gosebruch to its Board of Directors. Gosebruch previously held leadership roles at Lakefront Biotherapeutics, Neumora Therapeutics, and AbbVie. Board member Muthusamy (Samy) Shanmugam resigned from the Board and will continue in key operational roles at ANI Pharmaceuticals. This kind of board refresh is not unique to ANI Pharmaceuticals, and investors who want broader exposure to companies shaped closely by their... | ||